Takeda Pharmaceuticals Starts Phase 3 NSCLC Trial For Motesanib
This article was originally published in PharmAsia News
Executive Summary
Takeda Pharmaceuticals announced July 26 it will begin joint Phase III trials in Hong Kong, South Korea, and Taiwan for motesanib for patients with non-small-cell lung cancer.